K. Ünsal-Kaçmaz

BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial

G. Shapiro, P. Ravindran, J. Diamond, 2022, Cancers.

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

M. Burotto, A. Armstrong, L. Lacombe, 2022, Journal for ImmunoTherapy of Cancer.

Becker Digital

M. Burotto, G. Gravis, J. Pérez-Gracia, 2022 .

Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score.

Jun Yu Li, J. Witjes, M. Galsky, 2023, European urology.

Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial

M. Galsky, D. Bajorin, M. Oya, 2022, Japanese journal of clinical oncology.